Immunotherapy
Chemotherapy regimen improves survival in advanced esophageal cancer
CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.
‘Practice-changing data’ support first-line immunotherapy combination in colorectal cancer
CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
mRNA vaccine reprograms immune system to attack glioblastoma
An mRNA cancer vaccine developed at University of Florida may have the ability to reprogram the immune system against glioblastoma, findings of a first-in-human trial showed.
Keytruda extends survival in high-risk triple negative breast cancer
A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.
American Cancer Society awards $28M in grants
American Cancer Society has awarded $28 million in new extramural discovery science research and career development grants to fund investigators across several U.S. institutions beginning in July 2024.
Racing modified cells against each other in humans may be the next step in gene therapies
The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.
Findings highlight ‘desperate need’ to improve end-of-life cancer treatment
Oncologic treatment of adults with various metastatic or advanced solid tumors may not improve OS and could be detrimental to quality of life, according to findings published in JAMA Oncology.
Subcutaneous allergen immunotherapy reduces asthma risk, improves symptom control
Subcutaneous allergen immunotherapy for house dust mite reduced the number of prescriptions for allergic rhinitis and asthma medications, according to a study published in The European Journal of Allergy and Clinical Immunology.
Phase 3 trial of nivolumab for advanced lung cancer misses primary endpoint
A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.